OncoCyte Dirección

Dirección controles de criterios 2/4

El CEO de OncoCyte's es Josh Riggs , nombrado en Dec 2022, tiene una permanencia de 1.33 años. compensación anual total es $514.11K, compuesta por 47.1% salario y 52.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.042% de las acciones de la empresa, por valor de $13.80K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 3.3 años, respectivamente.

Información clave

Josh Riggs

Chief Executive Officer (CEO)

US$724.9k

Compensación total

Porcentaje del salario del CEO	46.9%
Permanencia del CEO	1.4yrs
Participación del CEO	0.03%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like

Mar 18

Does OncoCyte (NYSEMKT:OCX) Have A Healthy Balance Sheet?

Jan 27

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Josh Riggs en comparación con los beneficios de OncoCyte?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$725k	US$340k	-US$26m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$514k	US$242k	-US$19m

Compensación vs. Mercado: La compensación total ($USD514.11K) de Josh está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Josh ha aumentado mientras la empresa no es rentable.

CEO

Josh Riggs (40 yo)

1.4yrs

Permanencia

US$724,910

Compensación

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joshua Riggs	President	1.4yrs	US$724.91k	0.026% $ 9.9k
James Liu	Senior Director	1.7yrs	US$304.51k	0% $ 0
Ekkehard Schutz	Chief Science Officer	1.3yrs	US$575.17k	sin datos
Peter Hong	VP, General Counsel & Secretary	less than a year	sin datos	sin datos
Yuh-Min Chiang	Senior Vice President of R&D and Product Development	no data	sin datos	sin datos
Sandra O'Donald	Senior Vice President of Business Operations	less than a year	sin datos	sin datos
Michael West	Scientific Advisor	8.6yrs	US$328.84k	sin datos

1.4yrs

Permanencia media

40yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de OCX no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joshua Riggs	President	1.3yrs	US$724.91k	0.026% $ 9.9k
Louis Silverman	Lead Independent Director	1.5yrs	US$97.70k	0.000020% $ 7.5
Andrew Arno	Independent Chairman	8.9yrs	US$112.54k	0.62% $ 233.7k
Daniel Hayes	Member of Scientific & Medical Advisory Board	3.3yrs	sin datos	sin datos
David R. Gandara	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
Robert Ferris	Member of Scientific & Medical Advisory Board	no data	sin datos	sin datos
John Kirkwood	Member of Scientific & Medical Advisory Board	3.3yrs	sin datos	sin datos
Andrew Last	Independent Director	8.4yrs	US$92.86k	0.023% $ 8.5k
Fred Hirsch	Member of Scientific & Medical Advisory Board	3.3yrs	sin datos	sin datos
Heinz-Josef Lenz	Member of Scientific & Medical Advisory Board	3.3yrs	sin datos	sin datos
Ignacio Wistuba	Member of Scientific & Medical Advisory Board	3.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de OCX se considera experimentada (3.3 años de antigüedad promedio).

OncoCyte Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

Oncocyte Corporation Announces Executive Changes

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Recent updates

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$2.13

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

Consensus forecasts updated

Price target decreased to US$3.61

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

Revisiting OncoCyte Corp.

High number of new directors

Price target decreased to US$5.02

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Consensus revenue estimates fall by 28%

Full year 2021 earnings: EPS exceeds analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Price target decreased to US$7.80

Price target decreased to US$8.00

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Consensus forecasts updated

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

OncoCyte signs an at-the-market agreement to sell $50M of common stock

Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt

First quarter 2021 earnings released: US$0.048 loss per share (vs US$0.13 loss in 1Q 2020)

Forecast to breakeven in 2024

Consensus EPS estimates increase to -US$0.29

CEO, President & Director recently bought US$53k worth of stock

Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like